How Does Emerging Patent Case Law in the US and Europe Affect Precision Medicine? How Will Today’s Patent Law Affect Tomorrow’s Innovation in the Areas of Biomarkers and Nature-Based Products; Diagnostics; and Algorithms, Big Data and AI?

Aboy, M., Liddell, K., Crespo, C. et al. How does emerging patent case law in the US and Europe affect precision medicine?. Nat Biotechnol 37, 1118–1125 (2019)

Posted: 18 Aug 2020

See all articles by Mateo Aboy

Mateo Aboy

LML, University of Cambridge

I. Glenn Cohen

Harvard Law School

Kathleen Liddell

University of Cambridge - Faculty of Law

John Liddicoat

University of Cambridge - Faculty of Law; University of Tasmania

Cristina Crespo

University of Cambridge

Sara Gerke

Harvard University - Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics

Timo Minssen

University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law

Date Written: 2019

Abstract

Precision medicine has stirred the excitement of patients, physicians, industry, entrepreneurs, and investors — it is already a market that is worth tens of billions of dollars with very rapid growth expected. But the future of precision medicine heavily depends on the intellectual property frameworks that apply to its various forms. In order to chart this future, we compare recent patent case law in the US and Europe in three areas of precision medicine:

(1) biomarkers and nature-based products;

(2) diagnostics; and

(3) algorithms, big data, and AI.

We explain how today’s law will affect tomorrow’s innovation.

Suggested Citation

Aboy, Mateo and Cohen, I. Glenn and Liddell, Kathleen and Liddicoat, Johnathon and Crespo, Cristina and Gerke, Sara and Minssen, Timo, How Does Emerging Patent Case Law in the US and Europe Affect Precision Medicine? How Will Today’s Patent Law Affect Tomorrow’s Innovation in the Areas of Biomarkers and Nature-Based Products; Diagnostics; and Algorithms, Big Data and AI? (2019). Aboy, M., Liddell, K., Crespo, C. et al. How does emerging patent case law in the US and Europe affect precision medicine?. Nat Biotechnol 37, 1118–1125 (2019), Available at SSRN: https://ssrn.com/abstract=3653091

Mateo Aboy

LML, University of Cambridge ( email )

Trinity Ln
Cambridge, CB2 1TN
United Kingdom

HOME PAGE: http://https://www.lml.law.cam.ac.uk/people/Research-Scholars-Associates/Prof-mateo-aboy

I. Glenn Cohen

Harvard Law School ( email )

1525 Massachusetts Avenue
Griswold Hall 503
Cambridge, 02138
United States

Kathleen Liddell

University of Cambridge - Faculty of Law ( email )

10 West Road
Cambridge, CB3 9DZ
United Kingdom

Johnathon Liddicoat

University of Cambridge - Faculty of Law ( email )

10 West Road
Cambridge, CB3 9DZ
United Kingdom

University of Tasmania ( email )

French Street
Sandy Bay
Hobart, Tasmania 7001
Australia

Cristina Crespo

University of Cambridge ( email )

Trinity Ln
Cambridge, CB2 1TN
United Kingdom

Sara Gerke

Harvard University - Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics ( email )

23 Everett Street
Cambridge, MA 02138
United States

Timo Minssen (Contact Author)

University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law ( email )

Karen Blixens Plads 16
Copenhagen, 2300
Denmark
+46 708 607517 (Phone)

HOME PAGE: http://jura.ku.dk/cebil/staff/profile/?pure=en/persons/381631

Here is the Coronavirus
related research on SSRN

Paper statistics

Abstract Views
74
PlumX Metrics